CRISPR BY DESIGN
LIVE

Serial Number

99328121

Owner

Scribe Therapeutics Inc.

Attorney

John Paul Oleksiuk

Filing Date

Aug 8, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CRISPR BY DESIGN Trademark

Serial Number: 99328121

CRISPR BY DESIGN is a trademark filed by Scribe Therapeutics Inc. on August 8, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Scribe Therapeutics Inc. (10 trademarks)

Alameda, CA 94501

Entity Type: 03

Trademark Details

Filing Date

August 8, 2025

Registration Date

Not Registered

Published for Opposition

July 14, 2026

Goods & Services

Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions.

Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders.

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 16, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 13, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 13, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 13, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 12, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 26, 2025 GNRN
NON-FINAL ACTION E-MAILED
Dec 26, 2025 GNRT
NON-FINAL ACTION WRITTEN
Dec 26, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 22, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 18, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 8, 2025 MAFR
NEW APPLICATION ENTERED
Aug 8, 2025 NWAP